Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1980 Jul 1;152(1):183-97.
doi: 10.1084/jem.152.1.183.

Role of activated macrophages in antibody-dependent lysis of tumor cells

Role of activated macrophages in antibody-dependent lysis of tumor cells

C Nathan et al. J Exp Med. .

Abstract

Treatment of mice with Bacille Calmette-Guérin (BCG) or C parvum activates their peritoneal macrophages to release increased amounts of H2O2, and thereby to lyse extracellular tumor cells, in response to a pharmacologic agent, phorbol myristate acetate (PMA) (1-3). In the present study, the same bacterial vaccines activated peritoneal cells to become cytolytic to lymphoma cells sensitized with alloantiserum, in the absence of PMA. Resident peritoneal cells, or those elicited with thioglycollate broth, were ineffective, not only in PMA-induced lysis, but also in antibody-dependent lysis of tumor cells. The cytolytic effect of BCG peritoneal cells toward sensitized tumor cells appeared to be mediated mostly by macrophages. Cytotoxicity was immunologically specific, contact dependent, rapid, and efficient. Phagocytosis of intact tumor cells was not involved. Alloantiserum-dependent cytolysis was specifically blocked by the Fab fragment of a monoclonal antibody directed against the trypsin-resistant macrophage Fc receptor (FcR II). Thus, tumor cells coated with homologous immunoglobulin interact with FcR II on activated macrophages to trigger an extra-cellular cytolytic response.

PubMed Disclaimer

References

    1. Immunology. 1971 Jan;20(1):67-74 - PubMed
    1. J Exp Med. 1972 Mar 1;135(3):458-75 - PubMed
    1. J Exp Med. 1972 Aug 1;136(2):375-80 - PubMed
    1. J Immunol. 1973 Dec;111(6):1737-42 - PubMed
    1. J Clin Invest. 1974 Jun;53(6):1662-72 - PubMed

Publication types